Auris Medical Announces Formation of Scientific Advisory Board for Tinnitus Programs


Hamilton, Bermuda, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the formation of a Scientific Advisory Board (SAB) for its tinnitus research and development programs.

“We are delighted to have several world-renowned tinnitus experts join Auris Medical as advisors as we are preparing to advance our various tinnitus projects through further clinical and pre-clinical development,” stated Thomas Meyer, Auris Medical’s founder, Chairman and CEO. “There continues to be a strong unmet medical need amongst tinnitus sufferers worldwide, and we look forward to bringing novel therapeutics to patients. Thanks to the support from our new Scientific Advisory Board and the learnings from our late-stage trials with Keyzilen®, we feel that we are in a good position to take Keyzilen® as well as our early-stage projects forward.”

The appointments to Auris Medical’s Tinnitus SAB include:

  • Wolfgang Arnold, Professor Emeritus, former Director of the Department of Otolaryngology, Head and Neck Surgery of the Technical University of Munich, Germany
  • David Baguley, PhD, MBA, Professor in Hearing Sciences, Faculty of Medicine & Health Sciences, University of Nottingham, UK
  • Richard Salvi, SUNY Distinguished Professor and Director for the Center for Hearing and Deafness at the University at Buffalo, NY
  • Hinrich Staecker, MD, PhD, Professor, Director Division Otology/Neurotology, University of Kansas, KS

The Company aims to implement the further development of Keyzilen® as well as its early-stage tinnitus programs with non-dilutive funding.

About Auris Medical

Auris Medical is a biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders. The company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). These projects have gone through two Phase 1 trials and entered into proof-of-concept studies in 2019. In addition Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” or the negative of these terms and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical’s product candidates and that such trials will not meet their endpoints , the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2018 and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Investor contact:
Joseph Green
Edison Advisors for Auris Medical